Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Clinical trial NCT01928576 · COMPLETED
Trial details
- NCT number
- NCT01928576
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-06
- Primary completion
- 2023-04-04
- Enrollment
- 143
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.